1 This study has found no occurrence of poor metabolism of sparteine within a South African Venda populaton of 97 subjects.
2 On the basis of MR (metabolic ratio) the mean and distribution of the results are very similar to those found in Ghanaians.5,14
3 The distribution is also similar to that for fast metabolizers in Caucasians.14
4 It is concluded that different P450 cytochromes are responsible for immediate oxidation of debrisoquine and sparteine, but that both may be activated by the same P450 reductase.
Get full access to this article
View all access options for this article.
References
1.
Eichelbaum M. , Spannbrucker N., Steinke B. & Dengler HJDefective N-oxidation of sparteine in man: A new pharmacogenetic defect. European Journal of Clinical Pharmacology1979; 16: 183-7.
2.
Eichelbaum M.Defective oxidation of drugs: pharmacokinetic and therapeutic implications. Clinical Pharmacokinetics1982; 7: 1-22.
3.
Eichelbaum M.Polymorphic oxidation of debrisoquine and sparteine . In: Ethnic Differences in Reactions to Drugs and Xenobiotics , eds W. Kalow, H.W. Goedde & D.P. Argwal, pp. 157-67. New York: 1986.
4.
Horai Y. & Ishizaki T.Pharmacognetics and its clinical implications part II. Oxidation polymorphism . Rational Drug Therapy1988; 22: 1-8.
5.
Woolhouse NM , Eichelbaum M., Oates NS, Idle JR & Smith RLDissociation of co-regulatory control of debrisoquine/ phenformin and sparteine oxidation in Ghanaians. Clinical Pharmacology and Therapeutics1985; 37: 512-21.
6.
Sommers De K. , Moncrieff J. & Avenant J.Polymorphism in sparteine oxidation in the Barakwena (Kwengo) of Southern Africa. South African Journal of Science (in press).
7.
Moncrieff J.Simultaneous determination of sparteine, 2-dehydrosparteine and 5-dehydrosparteine in urine by high performance liquid chromatography with coulometric detection. Journal of Chromatography1990; 529: 194-200.
8.
Nebert DW, Adesnik M., Coon MJ et al. The P450 gene super family: Recommended nomenclature. DNA1987; 6: 1-11.
9.
Vinks A., Inaba T., Otton SV & Kalow W.Sparteine metabolim in Canadian Caucasians. Clinical Pharmacology and Therapeutics1982; 31: 23-9.
10.
Brosen K., Otton SV & Gram LFSparteine oxidation polymorphism in Denmark. Acta Pharmacologica et Toxicologica1985; 57: 357-60.
11.
Brosen K.Sparteine oxidation polymorphism in Greenlanders living in Denmark. British Journal of Clinical Pharmacology1986; 22: 415-19.
12.
Horai Y., Ishizaki T., Eichelbaum M. et al. Further analysis of sparteine oxidation in a Japanese population and comparison with data observed in different ethnic populations. Xenobiotica1988; 18: 1077-84.
13.
Sommers De K., Moncrief J. & Avenant J.Polymorphism of the 4-hydroxylation of debrisoquine in the San Bushman of Southern Africa. Human Toxiology1988; 7: 273-6.
14.
Eichelbaum M. & Woolhouse NMInter-ethnic difference in sparteine oxidation among Ghanaians and Germans .
15.
European Journal of Clinical Pharmacology1985; 28: 79-83. 15 Sommers De K., Moncrieff J. & Avenant J.Non-correlation between debrisoquine and metoprolol polymorphisms in the Venda: Human Toxicology1989; 8: 365-8.
16.
Inaba T., Vinks A., Otton SV & Kalow W.Comparative pharmacogenetics of sparteine and debrisoquine. Clinical Pharmacology and Therapeutics1983; 33: 394-9.
